The U.S. Patent & Trademark Office publishes same filing-to-registration timelines for applications filed based on different bases.
Today’s timeline shows a sample timeline for a Section 66(A) (Madrid Protocol) application:
For the full-sized version of the flowchart, please click here. We hope this information is useful.
If you have any questions or concerns, please do not hesitate to contact us.
The U.S. Patent & Trademark Office publishes same filing-to-registration timelines for applications filed based on different bases.
Today’s timeline shows a sample timeline for a Section 44(e) (Paris Convention) application:
For the full-sized version of the flowchart, please click here. We hope this information is useful.
If you have any questions or concerns, please do not hesitate to contact us.
The U.S. Patent & Trademark Office publishes same filing-to-registration timelines for applications filed based on different bases.
Today’s timeline shows a sample timeline for a Section 44(d) (Paris Convention priority) application:
For the full-sized version of the flowchart, please click here. We hope this information is useful.
If you have any questions or concerns, please do not hesitate to contact us.
The U.S. Patent & Trademark Office publishes same filing-to-registration timelines for applications filed based on different bases.
Today’s timeline shows a sample timeline for a Section 1(a) use-based application:
For the full-sized version of the flowchart, please click here. We hope this information is useful.
If you have any questions or concerns, please do not hesitate to contact us.
The U.S. Patent & Trademark Office publishes same filing-to-registration timelines for applications filed based on different bases.
Today’s timeline shows a sample timeline for a Section 1(b) intent-to-use application:
For the full-sized version of the flowchart, please click here. We hope this information is useful.
If you have any questions or concerns, please do not hesitate to contact us.
On Tuesday, the FDA announced that it approved the first flu vaccine comprising animal cell cultures. The vaccine, to be marketed under the trademark FLUCELVAX, is a Novartis product. FLUCELVAX will be manufactured in Novartis’ brand new North Carolina plant.
The vaccine is produced with virus strains that are grown in animal cell cultures derived from mammals instead of in chicken eggs. Similar cell culture technology has long been used to produce other types of vaccines, FDA said.
FDA press release here.
Apple, Inc. has reportedly paid Swiss rail operator, SBB, $21 million for use of the Swiss transportation company’s clock design.
As much as I like my Apple products, for a company that prides itself on design coupled with function, it seems to me the Apple could have developed its own clock design. But, Apple usually gets what it wants – even if it costs $21 million.
Anheuser-Busch has asked Paramount Pictures to remove (or obscure) images of its Budweiser® brand beer from the film “Flight,” starring Denzel Washington as a hero pilot accused of imbibing in excess before a plane crash.
In a written statement, Robert McCarthy, Budweiser’s Vice President said, “We would never condone the misuse of our products, and have a long history of promoting responsible drinking and preventing drunk driving. It is disappointing that Image Movers, the production company, and Paramount chose to use one of our brands in this manner.”
Of course, the fact that Budweiser would “never condone” misuse of alcohol, the stark reality is that people do abuse alcohol. While Budweiser may be less cooperative with Paramount pictures in future products, we think it is unlikely that Budweiser will be able to legally prevent the appearance of Budweiser in the film.